Founder, KKH Advisors // Strategic Communications. Biotech & Digital Health. Former @fticonsulting
New York
Joined May 2009
- Tweets14.2K
- Following2K
- Followers2K
- Likes23.4K
Kimberly Ha retweeted
“I’ve never seen anything like it,” Church told me, saying that he believed it violated the spirit of scientific collaboration. “It’s the kind of cutthroat mentality that you see in Hollywood.”
Some Friday night drama in my latest for @endpts: endpoints.news/church-quits-…
Kimberly Ha retweeted
Patients cannot wait another day for tomorrow’s medicines.
Today, bringing a drug to market can take more than 10 years and cost over $1 billion. A major contributor is the time and expense required to generate and review the documentation that helps to build medicines that are safe and effective.
That is why we are thrilled to partner with @AnthropicAI to transform drug development, starting with our clinical-stage programs. Together, we built tools to address two major early-stage bottlenecks: preparing a complete IND package and reviewing CMC batch records for release.
The results have been groundbreaking in speed, cost, and quality. Read more: anthropic.com/research/early…
Kimberly Ha retweeted
Roche is paying Zymeworks $55M upfront for a preclinical T cell engager, marking at least its 15th licensing deal of 2026. endpoints.news/roche-taps-zy…
Kimberly Ha retweeted
Roche will pay Zymeworks $55 million upfront plus another $40 million once the partnership asset enters Phase 1b development and up to $718 million in additional milestones.
hubs.li/Q04C78qt0
Kimberly Ha retweeted
🇨🇳RiboX Therapeutics announces first-in-human circular RNA therapy data published in NEJM businesswire.com/news/home/2…, businesswire.com/news/home/2…
RXRG001, an LNP-formulated circRNA encoding AQP1, shows early promise in radiation-induced xerostomia (RIX) and hyposalivation.
RXRG001 recently received FDA RMAT designation for radiation-induced xerostomia and hyposalivation.
Endpoints News had reported a death in an IIT run by RiboX endpoints.news/exclusive-thi…
RiboX was founded in Shanghai in 2021 by:
- Lingling Chen (researcher, CAS Center for Excellence in Molecular Cell Science)
- Dan Peer (delivery systems expert, Tel Aviv University)
- Weiyi Zhang (Founder & CEO, previously Associate Director at Bayer Innovation Partnership and Head of External Innovation China + Director, BI Venture Asia at Boehringer Ingelheim)
RiboX raised a $110 million Series B led by Temasek and focuses on circRNA + targeted LNP (tLNP) platforms for in vivo CAR-T.
Kimberly Ha retweeted
Roche picks up trispecific engager from Zymeworks in deal worth $813M $RHHBY $ZYME firstwordpharma.com/story/82…
Kimberly Ha retweeted
Zymeworks has entered into an exclusive global license and collaboration agreement with @Roche for ZW209, a DLL3-targeting trispecific T cell engager.
Under the agreement, Zymeworks is eligible to receive a $55 million upfront payment, a $40 million payment upon initiation of the Phase 1b trial, and up to $718 million in additional development, commercial and sales-based milestones, plus tiered royalties on future global net sales.
Zymeworks will conduct the Phase 1a monotherapy trial in collaboration with Roche, which will fund the trial and lead subsequent global development and commercialization.
The agreement reflects Zymeworks’ strategy of advancing innovative programs through its R&D engine and partnering selected assets to share development risk while retaining meaningful participation in future success.
Read the full announcement: lnkd.in/garA3Vi7
Zymeworks management will host a conference call on October 27 at 8:30 am ET.
#Oncology #RocheInnovation #pRED
Kimberly Ha retweeted
Brepocitinib met the primary and all key secondary endpoints in both Phase III CLARITY trials in non-infectious uveitis, @Roivant says. Subsidiary Priovant Therapeutics plans a US filing in 1H 2027.
thepharmaletter.com/pharma-n…
#Uveitis #Ophthalmology #Immunology #Biotech
Kimberly Ha retweeted
Brepocitinib is on a roll. After its autoimmune skin disease approval, Roivant subsidiary Priovant’s drug hit all primary and secondary endpoints in two Phase 3 non-infectious uveitis trials, leading analysts to note the agent “looked superior to Humira.”
hubs.li/Q04C0TlH0
Kimberly Ha retweeted
Matt Gline, CEO of Roivant, tells the #STATSummit audience he’s “rooting for” Anthropic’s foray into biotech. But he also has a few words of advice for Dario Amodei: “Biotech is a wood chipper that is built to ingest souls and shred them.”
Kimberly Ha retweeted
If you care about biotech and drug development watch this interview with Matt Gline, the CEO of Roivant, a biotech firm that is now worth $24 billion.
He talks about why he thinks predictions about AI from people like Anthropic’s Dario Amodei are overly optimistic.
“If Dario is right and I'm wrong, and he cures every disease in five years, man, are we all the winners from that outcome,” Gline said.
“I think if you work in this industry, it is very hard not to be skeptical of any of those claims. Because, and I've said this in other settings recently too, biotech is a wood chipper that like is built to like ingest souls and shred them. It's just like such a hard business that like someone comes and they're like, oh, but I've built a computer and I'm going to push a button and all of that goes away and it just works. Like that is probably not the way that's going to go.”
Kimberly Ha retweeted
Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)
Full announcement here: investor.roivant.com/news-re…
Kimberly Ha retweeted
Roivant, continuing ascent, claims another victory for rare disease drug biopharmadive.com/news/roiva… by Kristin Jensen $ROIV + 6% $ABBV
Kimberly Ha retweeted
An immune drug from Roivant could be headed to a new market, after the company reported positive trials in the eye disease non-infectious uveitis. trib.al/7Kd1g7l
Kimberly Ha retweeted
In partnership with Vinod Khosla (@vkhosla), I’m proud to introduce Reservoir.
Billionaires have owned their cells for years. Starting today, you can too.
Sign up today: withreservoir.com
Kimberly Ha retweeted
#SensibleBiotechnologies raises $47 million to scale cell-based #mRNAmanufacturing. The #financing will support the scale-up of the #startup's cell-based #mRNA platform and the development of clinical-grade manufacturing capabilities. pharmamanufacturing.com/indu… #mRNAmedicines
Kimberly Ha retweeted
mRNA made in living cells, not synthesized: UK-based Sensible Biotechnologies raises $47 million, led by Oxford Science Enterprises, to scale its VECTOR platform toward clinical-grade manufacturing.
thepharmaletter.com/biotech-…
#mRNA #Biotech
Kimberly Ha retweeted
Congrats to @sensible_bio on their $47M Series A. Sensible makes mRNA in living cells, built for the scale that in vivo CAR-T and gene editing demand. Proud to have backed the team since pre-seed. endpoints.news/sensible-bio-…
